Lexeo Therapeutics, Inc. (LXEO)
Nasdaq: LXEO · Biological Products, (No Diagnostic Substances) · New York, NY · filing with the SEC since 2022
Who owns Lexeo Therapeutics, Inc.
As filed with the SECHolders of 5% or more
13
Balyasny Asset Management L.P. holds 9.99% of Common Stock, as its SCHEDULE 13G/A filed Aug 14, 2026 says.
Directors and officers
15
report now, of 18 people on the record since 2023. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 13 named at left.
Holders of 5% or moreshare of the class, as filed
Balyasny Asset Management L.P.
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock · 9.69% in May 15, 2026
Janus Henderson Group PLC
SCHEDULE 13G/A · filed Dec 8, 2025 · Common Stock · 11.3% in Nov 14, 2025
Affinity Asset Advisors, LLC
SCHEDULE 13G/A · filed Aug 13, 2026 · Common Stock, $0.0001 par value per share · 7.1% in Jan 29, 2026
Suvretta Capital Management, LLC
SCHEDULE 13G · filed Apr 13, 2026 · Common stock, par value $0.0001
Vestal Point Capital, LP
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, par value $0.0001 per share · 6% in Aug 14, 2025
Kenneth Griffin
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock ($0.0001 par value) (the "Shares") · 9.6% in Aug 14, 2025
RA Capital Management, L.P.
SCHEDULE 13G · filed Oct 27, 2025 · Common Stock, $0.0001 par value per share
Blackrock, Inc.
SCHEDULE 13G · filed Jan 21, 2026 · Common Stock · 4% in Oct 17, 2025
Mizuho Financial Group, Inc.
SCHEDULE 13G/A · filed May 13, 2025 · Common Shares · 5.8% in Feb 13, 2025
JPMorgan Chase & Co.
SCHEDULE 13G · filed Oct 13, 2026 · Common Stock ($0.0001 par value)
State Street Corporation
SCHEDULE 13G · filed Aug 7, 2026 · COMMON STOCK
Paradigm BioCapital Advisors LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.0001 par value per share · 8.3% in May 15, 2026
Frazier Life Sciences Public Fund, L.P.
SCHEDULE 13G/A · filed Feb 13, 2026 · Common Stock, $0.0001 par value per share · 5.7% in Aug 14, 2025
OrbiMed Advisors LLC
SCHEDULE 13G · filed Aug 14, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%
Longitude Capital Partners IV, LLC
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock ($0.0001 par value) · reported falling below 5%
Eventide Asset Management, LLC
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, $0.0001 par value per share · reported falling below 5%
Omega Fund VI, L.P.
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, $0.0001 par value per share · reported falling below 5%
Millennium Management LLC
SCHEDULE 13G/A · filed Nov 7, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5.3% in Aug 7, 2025
D1 Capital Partners L.P.
SCHEDULE 13G/A · filed May 15, 2025 · Common Stock, $0.0001 par value · reported falling below 5%
Adage Capital Management, L.P.
SCHEDULE 13G/A · filed May 12, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 6.68% in Feb 12, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%, from 5.33% in Jan 30, 2026
What LXEO reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Stelios Therapeutics Inc
A company bought · acquisition · owns, named in the 10-K filed Mar 30, 2026
Insider tradesForm 4
27sales
0purchases
1sales on a scheduled plan
7people selling
$1.0Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window7 of 29 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Townsend Richard Nolan | Chief Executive Officer | 8 | $700,000 | 1 | 0 | $0 |
| Otero Jose Manuel | Chief Operating Officer | 7 | $100,000 | 0 | 0 | $0 |
| Bhalla Narinder Pal | Chief Medical Officer | 1 | $100,000 | 0 | 0 | $0 |
| Tamayo Louis Edward | Chief Financial Officer | 2 | $0 | 0 | 0 | $0 |
| Adler Eric | Chief Medical Officer | 3 | $0 | 0 | 0 | $0 |
| Robertson Jenny | Chief Legal Officer | 3 | $0 | 0 | 0 | $0 |
| See Tai Sandi | Chief Development Officer | 3 | $0 | 0 | 0 | $0 |